Comparison of the metabolic effects of sustained CCK1 receptor activation alone and in combination with upregulated leptin signalling in high-fat-fed mice

Diabetologia

Volumn 56, Issue 6, 2013, Pages 1425-1435

  Irwin, N ^a   Montgomery, I A ^a   Flatt, P R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Cholecystokinin (CCK); Diabetes; Glucose tolerance; Insulin sensitivity; Leptin; Obesity

Indexed keywords

CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ DERIVATIVE; CHOLECYSTOKININ OCTAPEPTIDE DERIVATIVE; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; LEPTIN; LEUCINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEPTIDE DERIVATIVE; SYNTHETIC PEPTIDE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ENERGY EXPENDITURE; FEEDING BEHAVIOR; GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIPID DIET; LIPID STORAGE; LIVER; LOCOMOTION; LUNG GAS EXCHANGE; MALE; METABOLISM; MONOTHERAPY; MOUSE; MUSCLE TISSUE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WEIGHT REDUCTION;

ANIMALS; AREA UNDER CURVE; BLOOD GLUCOSE; BODY WEIGHT; CALORIMETRY, INDIRECT; DIET, HIGH-FAT; INSULIN; INSULIN RESISTANCE; LEPTIN; MICE; OBESITY; PEPTIDES; RECEPTOR, CHOLECYSTOKININ A; RECEPTORS, CHOLECYSTOKININ; SIGNAL TRANSDUCTION; TIME FACTORS; UP-REGULATION;

EID: 84877770117     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2878-0     Document Type: Article

References (48)

1. Murphy KG, Bloom SR (2006) Gut hormones and the regulation of energy homeostasis. Nature 444:854-859
2. Peters JH, Simasko SM, Ritter RC (2006) Modulation of vagal afferent excitation and reduction of food intake by leptin and cholecystokinin. Physiol Behav 89:477-485
3. Brenner L, Yox DP, Ritter RC (1993) Suppression of sham feeding by intraintestinal nutrients is not correlated with plasma cholecystokinin elevation. Am J Physiol 264:R972-R976
4. Dockray GJ, Burdyga G (2011) Plasticity in vagal afferent neurones during feeding and fasting: mechanisms and significance. Acta Physiol (Oxf) 201:313-321
5. Baldwin BA, Parrott RF, Ebenezer IS (1998) Food for thought: a critique on the hypothesis that endogenous cholecystokinin acts as a physiological satiety factor. Prog Neurobiol 55:477-507
6. Rehfeld JF, Friis-Hansen L, Goetze JP, Hansen TV (2007) The biology of cholecystokinin and gastrin peptides. Curr Top Med Chem 7:1154-1165
7. Irwin N, Frizelle P, Montgomery IA, Moffett RC, O'Harte FPM, Flatt PR (2012) Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in animal models of obesity/diabetes. Diabetologia 55:2747-2258
8. Pénicaud L, Meillon S, Brondel L (2012) Leptin and the central control of feeding behavior. Biochimie 94:2069-2074
9. Benoit SC, Clegg DJ, Seeley RJ, Woods SC (2004) Insulin and leptin as adiposity signals. Recent Prog Horm Res 59:267-285
10. Pelleymounter MA, Cullen MJ, Baker MB et al (1995) Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269:540-543
11. Gonzalez LC, Pinilla L, Tena-Sempere M, Aguilar E (1999) Leptin(116-130) stimulates prolactin and luteinizing hormone secretion in fasted adult male rats. Neuroendocrinology 70:213-220
12. Grasso P, Rozhavskaya-Arena M, Leinung MC, Lee DW (2001) [D-LEU-4]-OB3, a synthetic leptin agonist, improves hyperglycemic control in C57BL/6J ob/ob mice. Regul Pept 101:123-129
13. Waldrop MA, Leinung MC, Lee DW, Grasso P (2010) Intranasal delivery of mouse [d-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, improves energy balance, glycaemic control, insulin sensitivity and bone formation in leptin-resistant C57BLK/6-m db/db mice. Diabetes Obes Metab 12:871-875
14. Gorska E, Popko K, Stelmaszczyk-Emmel A, Ciepiela O, Kucharska A, Wasik M (2010) Leptin receptors. Eur J Med Res 15:50-54
15. Sahu A (2004) A hypothalamic role in energy balance with special emphasis on leptin. Endocrinol 145:2613-2620
16. Burdyga G, Spiller D, Morris R et al (2002) Expression of the leptin receptor in rat and human nodose ganglion neurones. Neuroscience 109:339-347
17. Matson CA, Reid DF, Cannon TA, Ritter RC (2000) Cholecystokinin and leptin act synergistically to reduce body weight. Am J Physiol Regul Integr Comp Physiol 278:R882-R890
18. Merino B, Cano V, Guzmán R, Somoza B, Ruiz-Gayo M (2008) Leptin-mediated hypothalamic pathway of cholecystokinin (CCK-8) to regulate body weight in free-feeding rats. Endocrinology 149:1994-2000
19. Cano V, Merino B, Ezquerra L, Somoza B, Ruiz-Gayo M (2008) A cholecystokinin-1 receptor agonist (CCK-8) mediates increased permeability of brain barriers to leptin. Br J Pharmacol 154:1009-1015
20. Bado A, Levasseur S, Attoub S et al (1998) The stomach is a source of leptin. Nature 394:790-793
21. Guilmeau S, Buyse M, Tsocas A, Laigneau JP, Bado A (2003) Duodenal leptin stimulates cholecystokinin secretion: evidence of a positive leptin-cholecystokinin feedback loop. Diabetes 52:1664-1672
22. de Lartigue G, Barbier de la Serre C, Espero E, Lee J, Raybould HE (2012) Leptin resistance in vagal afferent neurons inhibits cholecystokinin signaling and satiation in diet induced obese rats. PLoS One 7:e32967
23. Kerr BD, Irwin N, O'Harte FP, Bailey CJ, Flatt PR, Gault VA (2009) Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Biochem Pharmacol 78:1008-1016
24. 3)GIP improves metabolic status in high-fat-fed mice. Diabetes Obes Metab 12:744-751
25. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
26. Gault VA, Porter DW, Irwin N, Flatt PR (2011) Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice. J Endocrinol 208:265-271
27. Flatt PR, Bailey CJ (1981) Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20:573-577
28. Lo CM, Obici S, Dong HH et al (2011) Impaired insulin secretion and enhanced insulin sensitivity in cholecystokinin-deficient mice. Diabetes 60:2000-2007
29. Zhao AZ, Bornfeldt KE, Beavo JA (1998) Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J Clin Invest 102:869-873
30. Silvestre RA, Rodríguez-Gallardo J, Egido EM, Marco J (2001) Effect of leptin on insulin, glucagon and somatostatin secretion in the perfused rat pancreas. Horm Metab Res 33:207-212
31. Barrachina MD, Martínez V, Wang L, Wei JY, Taché Y (1997) Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice. PNAS 94:10455-10460
32. de Lartigue G, Lur G, Dimaline R, Varro A, Raybould H, Dockray GJ (2010) EGR1 is a target for cooperative interactions between cholecystokinin and leptin, and inhibition by ghrelin, in vagal afferent neurons. Endocrinology 151:3589-3599
33. Wang L, Barachina MD, Martínez V, Wei JY, Taché Y (2000) Synergistic interaction between CCK and leptin to regulate food intake. Regul Pept 92:79-85
34. Lin L, Martin R, Schaffhauser AO, York DA (2001) Acute changes in the response to peripheral leptin with alteration in the diet composition. Am J Physiol Regul Integr Comp Physiol 280:R504-R509
35. Harris RB, Bowen HM, Mitchell TD (2003) Leptin resistance in mice is determined by gender and duration of exposure to high-fat diet. Physiol Behav 78:543-555
36. Moon HS, Matarese G, Brennan AM et al (2011) Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes 60:1647-1656
37. Ebihara K, Kusakabe T, Hirata M et al (2007) Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 92:532-541
38. Fineman MS, Mace KF, Diamant M et al (2012) Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 14:546-554
39. Crawley JN, Beinfeld MC (1983) Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302:703-706
40. Mineka S, Snowdon CT (1978) Inconsistency and possible habituation of CCK-induced satiety. Physiol Behav 21:65-72
41. Peters JH, Karpiel AB, Ritter RC, Simasko SM (2004) Cooperative activation of cultured vagal afferent neurons by leptin and cholecystokinin. Endocrinology 145:3652-3657
42. Dockray GJ (2009) Cholecystokinin and gut-brain signalling. Regul Pept 155:6-10
43. Montgomery IA, Irwin N, Flatt PR (2013) Beneficial effects of (pGlu-Gln)-CCK-8 on energy intake and metabolism in high fat fed mice are associated with alterations of hypothalamic gene expression. Horm Metab Res. doi: 10.1055/s-0032-1331767
44. Hisadome K, Reimann F, Gribble FM, Trapp S (2011) CCK stimulation of GLP-1 neurons involves α1-adrenoceptor-mediated increase in glutamatergic synaptic inputs. Diabetes 60:2701-2709
45. Bradwejn J (1993) Neurobiological investigations into the role of cholecystokinin in panic disorder. J Psychiatry Neurosci 18:178-188
46. Wang H, Wong PT, Spiess J, Zhu YZ (2005) Cholecystokinin-2 (CCK2) receptor-mediated anxiety-like behaviors in rats. Neurosci Biobehav Rev 29:1361-1373
47. Porter WD, Flatt PR, Hölscher C, Gault VA (2012) Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice. Int J Obes (Lond). doi: 10.1038/ijo.2012.91
48. Rozhavskaya-Arena M, Lee DW, Leinung MC, Grasso P (2000) Design of a synthetic leptin agonist: effects on energy balance, glucose homeostasis, and thermoregulation. Endocrinology 141:2501-2507